Research overview
The published path to RNOVA Tx.
Each step in the RNOVA concept rests on peer-reviewed research from the Kriz laboratory at Université Laval and the CERVO Brain Research Centre.
- 2016
Foundational microglial biology in ALS
Microglial phenotypes shift adaptively in preclinical stages of SOD1-mediated ALS, with IL-10 controlling early microglial responses.
- 2017
Diverging mRNA and protein networks
Ribosome profiling of microglia in vivo shows that highly upregulated immune mRNAs are not translated after innate immune challenge.
- 2017
SRSF3-associated translational repression
Repression is 3′UTR-mediated and involves SRSF3; SRSF3 knockdown increases synthesis of immune proteins in vitro and in vivo.
- 2020
Rethinking immunity in ALS
Excessive inflammation and inefficient immune responses can coexist in ALS.
- 2024
Chronic microglial dysfunction in neurodegeneration
Chronically activated ALS microglia lose immune functions and acquire an unconventional proteome.
- 2024
Experimental SRSF3 targeting
After experimental stroke, SRSF3-directed siRNA restores translation of selected immune proteins in microglia/macrophages.
- Now
RNOVA Tx translational development
Development of cell-targeted SRSF3-directed antisense therapeutics, led by ALS.
Advancing a new paradigm in CNS immunotherapy.
RNOVA Tx welcomes conversations with pharmaceutical, biotechnology, scientific and development partners interested in RNA therapeutics and neurodegenerative disease.